ADX-324-101
81 evidence topics · 14 sources
Objective
Part A and Part B: objectives in the quarterly report
Part B: secondary objective and exploratory efficacy endpoints
Location and study date
Registry site, dates, and status
| Field | Reported value |
|---|---|
| Location | “Adelaide, South Australia, Australia, 5000 CMAX Clinical Research” |
| Study start | “Study Start (Actual) 2022-12-14” |
| Primary completion | “Primary Completion (Estimated) 2027-12-31” |
| Study completion | “Study Completion (Estimated) 2027-12-31” |
| Status | “Active, not recruiting” |
Part A: country at first dosing
Part A interim analysis: follow-up at the time of analysis
Part A and Part B: data cutoff of the workshop abstract
Part A and Part B: data dates of the AAAAI poster figures
Part B: safety and efficacy data cutoffs in the prospectus
Part B: data cutoff of the November 2026 presentation
Study design
Registry design: two parts
Part A: randomization ratio and sentinel dosing
Part A: cohorts as described in the prospectus
Part A and Part B: cohorts as described in the workshop abstract
“A Phase 1, healthy volunteer placebo-controlled single dose escalation study of ADX-324 in 6 cohorts (0.4 mg/kg to 6 mg/kg) and 1 cohort administered 2 doses of 140 mg ADX-324 or placebo 3 months apart, and an open-label Phase 2a study in HAE patients with ADX-324 administered SC every 6 months was conducted” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“in a phase 2a, dose range finding study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part A and Part B: cohorts as described in the EAACI abstract
Part A interim: planned dose escalation and planned HAE study
Part B: continued dosing after the objectives were assessed
Eligibility criteria
Part A: inclusion criteria for healthy volunteers
Part A: selected exclusion criteria for healthy volunteers
Part B: inclusion criteria for participants with HAE
Part B: selected exclusion criteria for participants with HAE
Treatment
Registry interventions
| Intervention | Description |
|---|---|
| ADX-324 | “siRNA duplex oligonucleotide” |
| Placebo | “saline” |
Part A: weight-based cohorts in the pharmacokinetic figure
| Cohort | Dose as printed |
|---|---|
| Phase 1 cohort 1 | “Phase 1 Cohort 1 (0.4 mg/mkg)” |
| Phase 1 cohort 2 | “Phase 1 Cohort 2 (1.0 mg/mkg)” |
| Phase 1 cohort 3 | “Phase 1 Cohort 3 (2.0 mg/mkg)” |
| Phase 1 cohort 4 | “Phase 1 Cohort 4 (4.0 mg/mkg)” |
| Phase 1 cohort 5 | “Phase 1 Cohort 5 (6.0 mg/mkg)” |
| Phase 2 cohort 1 | “Phase 2 Cohort 1 (2.0 mg/mkg)” |
Part A: repeat-dose cohort
Part B: doses and dosing interval
Part B: doses as stated in the workshop abstract
“Three HAE patients have been dosed with ADX-324 at 2 mg/kg (n = 1, approximately 125 mg) and 245 mg (n = 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“one HAE patient was dosed at 122 mg and two patients were dosed at 245 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part B: doses as stated in the EAACI poster
Study outcomes
Rationale for using adverse event incidence as the primary endpoint
Registry primary outcome measures
Registry secondary outcome measures: prekallikrein and kallikrein
Part B: prekallikrein-kallikrein reduction as a predictor of attacks
Part B: suppression threshold proposed for an attack-free state
Same target: prekallikrein concentration and attack rate with donidalorsen
“These reductions in HAE attack rates were associated with corresponding reductions in mean plasma prekallikrein trough concentrations of 73% in the donidalorsen Q4W group and 47% in the donidalorsen Q8W group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reductions in predicted prekallikrein concentrations were correlated with reductions in predicted HAE attack rates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Registry planned enrollment
Part A: participants in the AAAAI poster
Part A and Part B: participants in the February 2026 release
Part A: participants by total dose group in the pharmacodynamic figure
| Total dose group | Group as printed |
|---|---|
| Placebo | “ph1, 0 mg (n=11)” |
| Above 0 to 100 mg | “ph1, >0-100 mg (n=13)” |
| Above 100 to 200 mg | “ph1, >100-200 mg (n=8)” |
| Above 200 to 250 mg | “ph1, >200-250 mg (n=6)” |
| Above 250 to 300 mg | “ph1, >250-300 mg (n=3)” |
| Above 300 to 350 mg | “ph1, >300-350 mg (n=4)” |
| Above 350 mg | “ph1, >350 mg (n=4)” |
| 300 mg plus or minus 25 mg | “ADX-324 300 mg +/- 25 mg (n=5)” |
Part B: participants enrolled
Description of analysis sets
Part A: summary statistic for prekallikrein-kallikrein reduction
Part B: longest follow-up in the AAAAI abstract
Part B: attack-free interval measured from approximate full inhibition
Results
Participant disposition
Registry recruitment status and results posting
Part A: completion and withdrawals
Part B: participants followed and one withdrawal
Part A and Part B: discontinuations due to adverse events
Baseline characteristics
No evidence found.
Efficacy results
Part A interim: prekallikrein nadir by weight-based dose
Part A: dose dependence of prekallikrein-kallikrein reduction
Part A: 6 mg/kg cohort, reduction at nadir and at 6 months
Part A: 300 mg plus or minus 25 mg, reduction at nadir and at Day 169 in the prospectus
Part A: 6 mg/kg cohort in the November 2026 presentation
Part A: 300 mg figures as attributed in the November 2026 presentation
Part A: 300 mg plus or minus 25 mg in the AAAAI poster
Part A: 300 mg dose in the February 2026 release
Part A: 300 mg plus or minus 25 mg in the workshop abstract
Part B: prekallikrein-kallikrein reduction compared with healthy volunteers at similar doses
Part B: attack-free period after the first dose, August 2026 cutoff
Part B: attack-free period after the first dose, November 2026 cutoff
Part B: attacks in relation to prekallikrein-kallikrein reduction
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Part A interim: severity and most frequent adverse event
Part A: most common adverse events and laboratory changes
Part A: serious adverse events by dose in the November 2026 presentation
Part B: safety through the August 2026 cutoff
Part A and Part B: serious adverse events and repeat dosing in the AAAAI poster
Part A and Part B: serious adverse events in the EAACI poster
Part A and Part B: tolerability in the February 2026 release
Part A and Part B: tolerability in the congress abstracts
Study limitations
Summary
Part A enrolled healthy volunteers aged 18 to 55 years with a body mass index of 18 to 30 kg/m2, so its pharmacodynamic and safety findings come from a population without HAE. Its dose groups were small: the AAAAI poster lists 3 to 13 participants per total dose group, 5 participants in the 300 mg plus or minus 25 mg group, and the prospectus reports the 6 mg/kg results for 4 participants, 3 of whom were below LLOQ at nadir.
Part B was open-label and uncontrolled and enrolled 3 participants, one of whom withdrew for administrative reasons. Its doses (122.5 mg or 245 mg every 6 months) differ from the phase 3 regimens of 300 mg every 6 months and 240 mg every 3 months. All phase 2a dosing was every 6 months, and the November 2026 presentation describes the 3-month attack-free result as an “Observed 100% Q3M attack-free rate in Phase 2a after the first dose”.
No baseline characteristics, baseline attack rates, on-treatment attack rates, or quality-of-life results were identified. Efficacy is reported as attack-free intervals of individual participants and as an association between attacks and the degree of prekallikrein-kallikrein reduction, and the prospectus figure marks the approximate time of full inhibition (about Day 22) and the point 3 months after the first dose. The proposed threshold differs between documents: “> 70%” in the workshop abstract and “>80%” in the prospectus and other sponsor documents.
The results are available only in congress abstracts, posters, press releases, a corporate presentation, and SEC filings. No peer-reviewed full article was identified, the registry record shows “No Results Posted”, and primary completion is estimated for 2027-12-31. The documents use data cutoffs from December 2024 to November 2026.
The documents report different numbers for Part A: 43 participants (32 onvuzosiran, 11 placebo) in 5 cohorts in the February 2026 release; 49 participants (38 onvuzosiran, 11 placebo) in the posters and the prospectus; and 5, 6, or 7 cohorts in different documents. The prospectus attributes the 94% nadir and 84% six-month reductions to the 6 mg/kg cohort, while the November 2026 presentation attributes them to 6 mg/kg on one page and to 300 mg plus or minus 25 mg on another. The first Part B dose is written as 122 mg, 122.5 mg, or approximately 125 mg.
Safety reporting gives one frequency, 28.9%, attached to headache and injection-site reaction in Part A, and no counts for creatine phosphokinase changes or liver enzyme increases. Serious adverse events are described variously as absent, absent when treatment-related, or absent when drug-related. No immunogenicity data and no electrocardiogram results were identified, although electrocardiogram change is a registry primary outcome.